Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -161.71% is 17% below its 5-year average of -138.13%, around the middle of its 5-year range (-285.07%–-30.35%).
7.71% above its 12-month average of -175.21%.
Reported quarterly return on assets; no daily interpolation. Q3 FY2026 (2026-05-31): -41.65%.
RETURN ON ASSETS (ROA)
-161.71%
RETURN ON ASSETS (ROA) AVG TTM
-175.21%
RETURN ON ASSETS (ROA) AVG 3Y
-164.83%
RETURN ON ASSETS (ROA) AVG 5Y
-138.13%
RETURN ON ASSETS (ROA) AVG 10Y
-161.99%
RETURN ON ASSETS (ROA) AVG 15Y
-124.22%
RETURN ON ASSETS (ROA) AVG 20Y
-100.67%
CURRENT VS TTM AVG
+7.71%
CURRENT VS 3Y AVG
+1.89%
CURRENT VS 5Y AVG
-17.07%
CURRENT VS 10Y AVG
+0.17%
CURRENT VS 15Y AVG
-30.18%
CURRENT VS 20Y AVG
-60.63%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-401.58%
vs the sector median at left
Lexaria Bioscience Corp.
Market Cap
$4.95M
Return on Assets (ROA)
-161.71%
TTM Avg
-175.21%
3Y Avg
-164.83%
5Y Avg
-138.13%
Market Cap
$4.81M
Return on Assets (ROA)
-35.52%
TTM Avg
-44.72%
3Y Avg
-43.23%
5Y Avg
-47.34%
Market Cap
$4.90M
Return on Assets (ROA)
-28.02%
TTM Avg
-155.25%
3Y Avg
-160.56%
5Y Avg
-117.99%
Market Cap
$5.04M
Return on Assets (ROA)
-71.72%
TTM Avg
-29.50%
3Y Avg
-8.92%
5Y Avg
-8.92%
Market Cap
$4.60M
Return on Assets (ROA)
-108.91%
TTM Avg
-143.36%
3Y Avg
-200.57%
5Y Avg
-146.87%
Market Cap
$4.59M
Return on Assets (ROA)
-43.98%
TTM Avg
7.01%
3Y Avg
2.17%
5Y Avg
-7.32%
Market Cap
$5.02M
Return on Assets (ROA)
-98.17%
TTM Avg
-154.79%
3Y Avg
-120.06%
5Y Avg
-94.26%
Market Cap
$5.12M
Return on Assets (ROA)
-367.93%
TTM Avg
-1046.51%
3Y Avg
-534.79%
5Y Avg
-427.52%
Market Cap
$4.51M
Return on Assets (ROA)
-157.28%
TTM Avg
-221.91%
3Y Avg
-169.98%
5Y Avg
-213.74%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $4.95M | -161.71% | -175.21% | -164.83% | -138.13% |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.81M | -35.52% | -44.72% | -43.23% | -47.34% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.90M | -28.02% | -155.25% | -160.56% | -117.99% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.04M | -71.72% | -29.50% | -8.92% | -8.92% |
| CalciMedica, Inc. (CALC)vs › | $4.60M | -108.91% | -143.36% | -200.57% | -146.87% |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.59M | -43.98% | 7.01% | 2.17% | -7.32% |
| Imunon, Inc. (IMNN)vs › | $5.02M | -98.17% | -154.79% | -120.06% | -94.26% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.12M | -367.93% | -1046.51% | -534.79% | -427.52% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.51M | -157.28% | -221.91% | -169.98% | -213.74% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | -1300.98% | -1108.45% | -604.75% | -486.62% |
ROA
-161.7%
ROE
-163.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-08-31 | -285.07% |
| 2024-08-31 | -65.35% |
| 2023-08-31 | -216.11% |
| 2022-08-31 | -92.79% |
| 2021-08-31 | -30.35% |
| 2020-08-31 | -139.10% |
| 2019-08-31 | -153.24% |
| 2018-08-31 | -271.35% |
| 2017-08-31 | -65.36% |
| 2016-08-31 | -214.38% |
| 2015-08-31 | -248.76% |
| 2013-10-31 | -52.37% |
| 2012-10-31 | -9.33% |
| 2011-10-31 | -5.80% |
| 2010-10-31 | -13.93% |
| 2009-10-31 | -16.16% |
| 2008-10-31 | -23.19% |
| 2007-10-31 | -25.78% |
| 2006-10-31 | -38.83% |
| 2005-10-31 | -46.18% |
